Does addition of vildagliptin to metformin monotherapy improve glycemic control in patients with type 2 diabetes mellitus?

Nature Clinical Practice Endocrinology and Metabolism

Volumn 3, Issue 8, 2007, Pages 572-573

  Retnakaran, Ravi ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b Leadership Sinai Centre for Diabetes   (Canada)

Author keywords

Dipeptidyl peptidase 4 inhibitor; Glycemic control; HbA1c; Type 2 diabetes mellitus; Vildagliptin

Indexed keywords

DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCOSE; HEMOGLOBIN A1C; METFORMIN; PLACEBO; TRIACYLGLYCEROL; VILDAGLIPTIN;

ADULT; AGED; BODY MASS; CELL FUNCTION; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET RESTRICTION; DISEASE DURATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; MAJOR CLINICAL STUDY; MONOTHERAPY; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; NOTE; PANCREAS ISLET BETA CELL; PATIENT SELECTION; PRIORITY JOURNAL; RANDOMIZATION; SCREENING; TREATMENT DURATION; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL; UNSPECIFIED SIDE EFFECT;

EID: 34447642184     PISSN: 17458366     EISSN: 17458374     Source Type: Journal    
DOI: 10.1038/ncpendmet0552     Document Type: Note

References (5)

1. Drucker DJ and Nauck MA (2006) The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 368: 1696-1705
2. Ahren B et al. (2004) Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes. Diabetes Care 27: 2874-2880
3. Charbonnel B et al. (2006) Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care 29: 2638-2643
4. Ahren B (2007) DPP-4 inhibitors - clinical data and clinical implications. Diabetes Care [doi: 10.2337/dc07-0233]
5. Nathan DM (2007) Finding new treatments for diabetes - how many, how fast... How good? N Engl J Med 356: 437-440